An eating disorder treatment denial lawsuit is a legal claim brought by patients or on behalf of a class of patients against insurance companies that wrongfully refuse to cover medically necessary eating disorder treatment. These lawsuits allege that insurers use systematic denial practices—such as arbitrary visit limits or unsupported “not medically necessary” determinations—to restrict access to lifesaving care despite having contractual obligations to pay for treatment. In September 2024, the Fifth Circuit Court of Appeals delivered a landmark ruling against United Healthcare, finding that the insurer had improperly denied continuing treatment for a patient with anorexia nervosa, establishing that insurers cannot rely on vague or evidence-free justifications to deny eating disorder care.
The lawsuits address a documented pattern of insurance denial practices that affect hundreds of thousands of Americans. A 2025 investigation by MindSite News found evidence that many health insurers and managed care organizations pursue practices that systematically limit eating disorder care despite growing medical consensus about the need for extended, intensive treatment. Health insurers have been accused of ignoring their own clinical guidelines and the standards set by major medical organizations, instead imposing arbitrary numerical caps on treatment sessions or denying coverage based on criteria that have no medical foundation.
Table of Contents
- Why Are Insurance Companies Denying Eating Disorder Treatment?
- How These Denials Work Within the Insurance System
- The Real-World Impact on Patients and Families
- What the Fifth Circuit Ruling Means for Patients
- Insurance Coverage Access Disparities Across Patient Populations
- Settlement Developments and Legal Actions
- Future Outlook and Legal Standards
- Conclusion
Why Are Insurance Companies Denying Eating Disorder Treatment?
insurance companies deny eating disorder claims through two primary mechanisms, according to court filings and regulatory investigations. The first method involves imposing numerical limits on the number of visits or days of coverage allowed—for example, capping inpatient treatment at 21 days or outpatient therapy at 20 sessions per year, regardless of medical need. The second method involves issuing denials based on the claim that treatment is “not medically necessary,” a determination known as a non-quantitative treatment limitation (NQTL). In practice, this means an insurer reviews a treatment plan and concludes that the level of care isn’t necessary, without adequate medical evidence to support that conclusion. The Fifth Circuit’s September 2024 ruling directly addressed this second practice. United Healthcare had denied continued coverage for a patient’s anorexia nervosa treatment by issuing denial letters that lacked any meaningful engagement with the patient’s medical records or clinical presentation.
The court found that ERISA procedures required the insurer to conduct meaningful dialogue with the beneficiary and to base denials on actual medical evidence. The ruling established that insurers cannot simply issue form denials without analyzing the specific clinical circumstances of the individual case. This decision has created legal vulnerability for any insurer that applies blanket denial practices without individualized medical review. The economic incentive behind these denials is straightforward: eating disorder treatment is expensive. Intensive outpatient programs can cost $15,000 to $30,000 per month, residential treatment can exceed $1,000 per day, and long-term inpatient care requires sustained expenditure. By restricting access through numerical caps or unsupported medical necessity denials, insurers reduce their short-term costs. What they do not account for in their actuarial models is the cost of treatment failure, emergency hospitalizations, or mortality—eating disorders have the highest mortality rate of any psychiatric illness.
How These Denials Work Within the Insurance System
Eating disorder treatment denials operate through the insurance appeals process, which creates a structural disadvantage for patients and their providers. When a treatment facility or individual patient’s doctor requests authorization for continuing eating disorder care, the insurance company’s utilization review department evaluates the request. This evaluation typically occurs on a compressed timeline—often 24 to 72 hours for urgent decisions—against internal metrics that have nothing to do with the clinical standard of care. A patient may be receiving appropriate, medically indicated treatment at an accredited facility, yet the insurance reviewer, often a nurse or case manager without eating disorder expertise, issues a denial anyway. Once a denial is issued, patients and providers must navigate the appeals process, which creates a significant practical barrier. The initial appeal may take another 14 to 30 days, during which the patient frequently either stops treatment (because they cannot afford to pay out of pocket) or continues unpaid while accumulating debt.
An external review by an independent medical expert can be requested, but this process takes additional weeks. Meanwhile, eating disorder symptoms continue to progress, the patient may experience medical complications, and the opportunity for less intensive intervention has often passed. The 2025 MindSite News investigation found that insurers pursue these practices knowing that many patients will give up on appeals before reaching external review, effectively making the denial stick through attrition rather than through medical justification. A critical limitation in the current system is that many eating disorder specialists do not have the administrative capacity to fight insurance denials repeatedly. A treatment facility that treats 200 eating disorder patients annually may issue 50+ authorization requests. If 30 of those result in denials requiring formal appeals, the administrative burden of fighting each denial becomes prohibitive. Some facilities have hired dedicated staff to manage insurance disputes, while others have begun refusing to accept certain insurances altogether, further reducing access for insured patients.
The Real-World Impact on Patients and Families
Insurance denials of eating disorder treatment translate directly into delayed care and worse health outcomes. When a patient’s insurance denies coverage for residential treatment or an intensive outpatient program, the patient faces an immediate decision: pay the full cost out of pocket (which most families cannot do), stop treatment (which almost always results in symptom escalation), or seek a lower level of care that the insurance will authorize (even if it is clinically inadequate for their condition). Each of these choices carries severe consequences. Consider a concrete example: a teenager with anorexia nervosa is admitted to a residential treatment facility, where she makes progress over the first 30 days. Her insurance company denies continued coverage, claiming that “step-down to intensive outpatient care is medically appropriate.” The facility’s treatment team believes that she needs additional residential care based on her weight, vital signs, and psychological status, but they cannot override the insurance determination without forcing her family to pay $35,000 per month out of pocket. The family cannot afford this, so the patient is discharged to an intensive outpatient program.
Within six weeks, she relapses, her weight drops to dangerous levels, she develops cardiac complications, and she ends up in an emergency hospitalization, which costs the insurance company far more than the denied residential care would have cost. This scenario plays out repeatedly across the country. The Fifth Circuit ruling involved exactly this type of situation. The patient in that case had her eating disorder treatment coverage denied, which forced a clinical step-down that her treatment team opposed. The Fifth Circuit found that the insurer’s denial letter contained no reference to medical literature, no analysis of the patient’s specific clinical presentation, and no meaningful engagement with the treating provider’s recommendations. The court ruled that this violated ERISA’s requirement that denials be “based on applicable plan terms and on adequate evidence.” This ruling creates legal standing for patients whose insurers follow the same practices.
What the Fifth Circuit Ruling Means for Patients
The September 2024 Fifth Circuit ruling represents the first major appellate court decision establishing that insurance companies cannot use vague, evidence-free denials to restrict eating disorder treatment. The ruling states that denials of eating disorder treatment must be supported by actual medical evidence, that insurers must conduct meaningful dialogue with beneficiaries before issuing denials, and that numerical treatment limitations cannot be imposed without individualized review. This decision applies to all health plans governed by ERISA (which includes most employer-sponsored plans and many private insurance products) in the Fifth Circuit’s jurisdiction, which includes Louisiana, Mississippi, and Texas. However, the ruling’s reach beyond those three states depends on whether other federal circuits adopt the same reasoning or whether the Supreme Court takes the case. Currently, similar cases are pending in other circuits, and plaintiff lawyers report that insurance companies are facing increased legal vulnerability nationwide as a result of the Fifth Circuit decision. Insurance companies have begun defending themselves more carefully in litigation, including some evidence that they are revising denial procedures to include more detailed medical rationales.
The practical effect is that patients whose claims are denied have stronger legal arguments when appealing or pursuing litigation. A significant limitation is that the Fifth Circuit ruling does not create a right to coverage—it creates a right to meaningful review. An insurer can still deny eating disorder treatment if it does so based on medical evidence and with individualized consideration. What the ruling prohibits is the categorical denial without analysis. Additionally, the ruling applies only to ERISA plans; patients with Medicaid, Medicare, or plans governed by state law may have different legal protections. And the ruling does not automatically reverse existing denials—patients must pursue appeals, litigation, or external review to enforce it in their individual cases.
Insurance Coverage Access Disparities Across Patient Populations
The ability to access eating disorder treatment varies dramatically depending on insurance type and geography. According to data analyzed by ParityTrack’s legal cases database, 57.6% of people with public insurance (primarily Medicaid) reported inability to access a qualified eating disorder provider in their insurance network. By comparison, 37.5% of people with private insurance reported the same access barrier. This 20-percentage-point difference means that public insurance patients are significantly more likely to be unable to find an in-network provider who treats eating disorders, even before accounting for insurance denials of specific treatments. This disparity creates a catch-22 for low-income patients: they are more likely to be covered by public insurance with severe access limitations, and they are less able to pay out of pocket to supplement insufficient insurance coverage.
When a Medicaid patient’s insurance denies coverage for a recommended eating disorder treatment, they have fewer options than a privately insured patient. A patient with private insurance might be able to shift to a different insurance plan through their employer, negotiate payment plans with providers, or access employer assistance programs. A Medicaid patient has little room to maneuver and faces the choice of going without treatment or going into debt. The MindSite News investigation in 2025 identified that managed care organizations administering Medicaid plans in several states were pursuing more aggressive denial practices than commercial insurers, despite Medicaid beneficiaries having greater medical need and fewer financial resources to appeal. This suggests that the eating disorder treatment denial problem is not uniform—it is most acute for the patient populations least equipped to fight it.
Settlement Developments and Legal Actions
New Jersey has emerged as a center of eating disorder treatment denial litigation. Health insurers in New Jersey have settled multiple class action lawsuits asserting wrongful denial of eating disorder treatment coverage claims. While specific settlement amounts were not disclosed in public filings, the existence of multiple settlements indicates that insurers faced sufficient legal risk to negotiate resolution rather than continue litigation. These settlements typically include commitments to revise denial procedures, provide retraining to utilization review staff, and sometimes include compensation funds for class members who experienced prior denials.
Beyond New Jersey, the 2024 Fifth Circuit ruling and the 2025 MindSite News investigation have prompted additional litigation in other jurisdictions. Plaintiff lawyers report filing new class actions against major insurers in multiple states, alleging systematic eating disorder treatment denial practices. The legal theory is straightforward: if an insurer has a pattern of denying eating disorder claims without individualized medical review, then all beneficiaries who had claims denied are entitled to recovery. The Fifth Circuit ruling provides the legal foundation for these claims by establishing that such denials violate ERISA.
Future Outlook and Legal Standards
The eating disorder treatment denial lawsuits reflect a broader legal trend holding insurers accountable for failure to cover mental health treatment. Insurance companies historically faced less legal scrutiny for mental health denials than for physical health denials, in part because mental health advocates had less legal infrastructure. This is changing. The combination of the Fifth Circuit ruling, state legislative action (several states have passed eating disorder-specific insurance coverage laws), and investigative journalism has created a convergence of legal and reputational pressure on insurers.
Looking forward, eating disorder treatment denials will likely face increasing legal vulnerability if insurers do not change their practices. The Fifth Circuit ruling may be appealed to the Supreme Court, which could establish binding national precedent. Separately, Congress is considering legislation that would strengthen ERISA protections for eating disorder and mental health treatment. What all of this means for patients is that the cost of insurance denials is rising for companies that pursue them, which should create incentive to approve medically indicated treatment rather than deny it.
Conclusion
Eating disorder treatment denial lawsuits address a documented pattern of insurance companies refusing to cover medically necessary care for a serious, life-threatening condition. The September 2024 Fifth Circuit Court of Appeals ruling against United Healthcare established that these denials, when issued without medical evidence and without individualized review, violate ERISA and expose insurers to legal liability. The evidence shows that insurers impose these denials systematically, using numerical visit limits and unsupported “not medically necessary” determinations, with documented disproportionate impact on publicly insured patients who have fewer options to seek alternative coverage.
If you have had an eating disorder treatment claim denied, you may have legal remedies. You can pursue an appeal within your insurance company’s appeals process, request an external independent review, or contact a lawyer about litigation or class action rights. The legal landscape for these claims has shifted significantly in 2024 and 2025, and what would have been an unchallenged denial in prior years now carries legal risk for the insurer. Consulting with an attorney who handles insurance bad faith or ERISA cases can help you understand your rights and options.